Stock IVACC INTERVACC AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Intervacc AB

Equities

IVACC

SE0009607252

Market Closed - Nasdaq Stockholm
Other stock markets
 16:29:32 06/05/2024 BST 		5-day change 1st Jan Change
4.2 SEK -3.23% Intraday chart for Intervacc AB +0.60% -33.65%
03-04 Intervacc AB Announces Changes in the Nomination Committee CI
02-28 Intervacc's Acting CEO Assumes Role Permanently MT

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
  • The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • Based on current prices, the company has particularly high valuation levels.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
INTERVACC AB Stock Intervacc AB
-33.65% 30.43M
D
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+8.67% 105B
B+
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-0.88% 104B
B+
ARGENX SE Stock argenx SE
+5.79% 22.94B
B
BIONTECH SE Stock BioNTech SE
-12.50% 22.34B
B+
GENMAB A/S Stock Genmab A/S
-7.01% 19.25B
A-
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-37.08% 17.08B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-9.25% 16.96B
B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+8.15% 14.16B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+39.51% 12.63B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. IVACC Stock
  4. Ratings Intervacc AB